← All indications
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Subtype terms (3)
More specific conditions that are subtypes of Renal Insufficiency in the MeSH hierarchy.
- Acute Kidney Injury
216 drugs (150 approved, 66 experimental)
- Cardio-Renal Syndrome
22 drugs (19 approved, 3 experimental)
- Renal Insufficiency, Chronic
472 drugs (259 approved, 213 experimental)
Drugs by status
Approved for this indication (11)
Phase 4 trials (83)
- simvastatin
- metformin
- phenobarbital
- allopurinol
- vitamin d3
- nitroglycerin
- methylprednisolone
- desmopressin
- theophylline
- atrial natriuretic peptide
- acetylcysteine
- ketamine
- oxycodone
- daclizumab
- prednisone
- ibuprofen
- valproic acid
- doravirine
- elbasvir
- empagliflozin
- ferric citrate
- gadodiamide
- gadoteric acid
- isoflurane
- sevoflurane
- tacrolimus
- dolutegravir
- tenofovir
- doxercalciferol
- lactulose
- +53 more
Phase 3 trials (30)
- ringer's lactate
- heparin
- Relmapirazin
- urea
- epoetin
- amg 223
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- heme iron polypeptide
- rosuvastatin
- imiquimod
- daptomycin
- iron dextran
- keto-amino acids
- mb-102
- motexafin gadolinium
- homocysteine
- atorvastatin
- hepatitis b vaccine (recombinant)
- sitagliptin
- sevelamer
- acetylsalicylic acid
- tonapofylline
- furosemide
- alpha-ketoacid
- rivaroxaban
- apixaban
- clopidogrel
- canagliflozin
- acellular tissue engineered vessel
- qrx-3
Phase 2 trials (42)
- thalidomide
- 62cu-thiosemicarbazone
- alfacalcidol
- bhq-880
- bhq990
- carfilzomib
- lenalidomide
- cd4+cd25+cd127lowfoxp3+ t regulatory cells
- cenderitide
- chlorthalidone
- C1 Esterase Inhibitor (Human)
- evogliptin
- eculizumab
- hemopoietic stem cell
- bone marrow derived mesenchymal stem cells
- ily101
- Ocedurenone
- rolofylline
- octreotide
- pirfenidone
- linagliptin
- rc48-adc
- allogeneic hematopoietic stem cells
- immune globulin (human)
- siplizumab
- aliskiren
- ulodesine
- bortezomib
- autologous mesenchymal stem cells
- fludarabine
- +12 more
Phase 1 trials (89)
- fingolimod
- dotinurad
- daridorexant
- propofol
- dalfampridine
- azacitidine
- Retagliptin
- plazomicin
- afatinib
- al-335
- avibactam
- aztreonam
- darolutamide
- nerandomilast
- bi 1467335
- faldaprevir
- bi 425809
- dabigatran
- Iberdomide
- chimeric natriuretic peptide
- clozapine
- exenatide
- odanacatib
- dabrafenib
- dulaglutide
- fevipiprant
- paclitaxel
- remogliflozin etabonate
- emricasan
- etomidate
- +59 more
Other trials (30)
- linezolid
- leptospermum honey
- cinacalcet
- finerenone
- meperidine
- iodine
- whey protein
- cow milk
- alendronic acid
- aluminum hydroxide
- acetaminophen
- levobupivacaine
- semaglutide
- sotagliflozin
- testosterone
- ursolic acid
- zoledronic acid
- creatine
- eucommia
- fentanyl
- losartan
- albuterol
- sodium thiosulfate
- oxygen
- soybean
- telmisartan
- clove oil
- iodohippurate sodium i-123
- bisoprolol
- arginine
Organizations
Organization Involved with Phase 4 Indications (216)
- Novo Nordisk
- Soonchunhyang University
- University of Pennsylvania
- Memorial University of Newfoundland
- IQVIA
- Higashikouri Hospital
- University of Paris
- Watson Pharmaceuticals
- ABX-CRO
- George Clinical Pty Ltd
- Cairo University
- University of Heidelberg
- Ilsan Hospital
- Envida
- University of Basel
- Konyang University
- Duke University
- Akebono clinic
- Profil GmbH
- Yonsei University
- Siriraj Hospital
- Aalborg University
- University of Cincinnati
- Mahidol University
- University of Munster
- Ahvaz Jundishapur University of Medical Sciences
- University of Oslo
- Corporacion Parc Tauli
- University of Insubria
- Hamadan University of Medical Science
- +186 more
Organization Involved with Phase 3 Indications (136)
- Laboratório Químico Farmacêutico Bergamo Ltda.
- University Clermont Auvergne
- Phenomix
- Instituto Mexicano del Seguro Social
- Bambino Gesù Hospital and Research Institute
- Indiana University
- General Hospital of Chinese Armed Police Forces
- Technical University of Dresden
- Toray Industries, Inc
- University of Toronto
- University of Southern Denmark
- Cadila Healthcare
- Universidad Autonoma de Barcelona
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- IMFORM GmbH
- Institut d'Anesthesiologie des Alpes Maritimes
- University of Alabama, Birmingham
- Rockwell Medical Inc
- Melbourne Health
- Ineos Healthcare Limited
- University of Chile
- Onassis Cardiac Surgery Centre
- Tufts University
- Baskent University
- Apollo Hospitals, Chennai, India
- Gujarat Kidney Foundation, Ahmedabad
- Spectra Clinical Research
- University of Ottawa
- Western Galilee Hospital
- Medical College of Wisconsin
- +106 more
Organization Involved with Phase 2 Indications (104)
- Speedel Pharma Ltd.
- Technion University
- University of Liege
- The Physicians' Services Incorporated Foundation
- Ilypsa
- MedImmune
- Rocky Mountain Cancer Centers
- ZS Pharma, Inc.
- Assiut University
- National Health Service, United Kingdom
- Shanghai University of Traditional Chinese Medicine
- Summa Health System
- National Heart, Lung, and Blood Institute (NHLBI)
- Fudan University
- Elcelyx Therapeutics, Inc.
- Sungkyunkwan University
- Cooperative Clinical Trials in Pediatric Transplantation
- Merck Serono
- Anhui College of Traditional Chinese Medicine
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- 3SBio
- POM Wonderful LLC
- University of Florida
- Shanghai University
- Wright State University
- Western Hospital, Footscray, Victoria. Australia
- Capricor Inc.
- Austrian Forum Against Cancer
- Northern Health and Social Care Trust
- University of Arizona
- +74 more
Organization Involved with Phase 1 Indications (137)
- Kyoto University
- Vanda Pharmaceuticals
- Magenta Therapeutics
- WiSP GmbH
- Haisco Pharmaceutical
- GW Pharmaceuticals Ltd.
- Trius Therapeutics
- Stealth BioTherapeutics Inc.
- Fuji Yakuhin Co., Ltd.
- CRS Clinical Research Services Kiel GmbH
- Ardea Biosciences
- Rhythm Pharmaceuticals, Inc.
- University of Helsinki
- Bausch Health Companies
- Prolong Pharmaceuticals
- Newron Pharmaceuticals
- Cognitive Research Corporation
- Nycomed
- Eurofins
- Cephalon
- VenatoRx Pharmaceuticals, Inc.
- Entasis Therapeutics
- University of Caen-Normandie
- Spero Therapeutics
- FibroGen
- Ain Shams University
- Blau Farmacêutica S.A.
- Rovi Pharmaceuticals Laboratories
- Eloxx Pharmaceuticals, Inc.
- University of Milan
- +107 more
Organization Involved with Other Experimental Indications (35)
- Gia Dinh People Hospital
- Tel Aviv University
- Glaxo Wellcome
- Government of Hong Kong
- University of Kentucky
- Triax
- National University of Malaysia
- University of Chicago
- Saarland University
- University of Western Brittany
- University of New Mexico
- Los Angeles Biomedical Research Institute
- Changi General Hospital
- University of Khartoum
- University of Tuebingen
- Alberta Heritage Foundation for Medical Research
- Chang Gung University
- Shanghai Municipal Health Bureau
- National Center for Research Resources (NCRR)
- Government of Malaysia
- Pennsylvania State University
- Government of Canada
- Damanhour University
- Kirin
- Icahn School of Medicine at Mount Sinai
- Almughtaribeen University
- University Putra Malaysia
- Satellite Healthcare
- Dutch Kidney Foundation
- Hebrew University
- +5 more